Related Experiment Video

Updated: Jan 23, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

1.1K

Palivizumab and Long-term Outcomes in Cystic Fibrosis

Aliza K Fink1, Gavin Graff2, Carrie L Byington3

  • 1Cystic Fibrosis Foundation, Bethesda, Maryland; afink@cff.org.

Pediatrics
|June 27, 2019
PubMed

Insights

Palivizumab prophylaxis did not improve longer-term outcomes for infants with cystic fibrosis (CF). This study found no significant differences in lung function, Pseudomonas aeruginosa infections, or hospitalizations by age seven.

Area of Science:

  • Pediatric Pulmonology
  • Infectious Disease Management

Background:

  • Current guidelines suggest palivizumab for high-risk infants with cystic fibrosis (CF), but its long-term benefits remain unclear.
  • Uncertainty exists regarding the impact of palivizumab on sustained health outcomes in young children with CF.

Purpose of the Study:

  • To evaluate the association between palivizumab use in the first two years of life and longer-term outcomes in children with CF.
  • Assessed lung function, time to first Pseudomonas infection, and hospitalization rates up to age seven.

Main Methods:

  • Utilized data from the Cystic Fibrosis Foundation Patient Registry for infants born between 2008-2015 diagnosed with CF within six months.
  • Employed propensity score adjustment to control for confounding factors, including indication for treatment.
  • Performed regression analyses to assess the relationship between palivizumab receipt and key health outcomes.

Main Results:

  • Analysis included 4267 infants; 37% received palivizumab.
  • No significant difference in mean lung function (percent predicted FEV1) at age seven was observed between palivizumab recipients and non-recipients.
  • Time to first positive Pseudomonas aeruginosa culture and annual hospitalization risk were similar in both groups.

Conclusions:

  • Palivizumab prophylaxis was not associated with improved longer-term health outcomes in the general population of children with CF.
  • Findings suggest that routine palivizumab use may not confer sustained benefits for lung function or infection rates in CF patients.
Abstract

More Related Videos

Rectal Organoid Morphology Analysis ROMA: A Diagnostic Assay in Cystic Fibrosis07:56

Rectal Organoid Morphology Analysis ROMA: A Diagnostic Assay in Cystic Fibrosis

Published on: June 10, 2022

3.2K
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

23.8K

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
740
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
485
Predicting Reaction Outcomes02:24

Predicting Reaction Outcomes

Kinetics describes the rate and path by which a reaction occurs. In contrast, thermodynamics deals with state functions and describes the properties, behavior, and components of a system. It is not concerned with the path taken by the process and cannot address the rate at which a reaction occurs. Although it does provide information about what can happen during a reaction process, it does not describe the detailed steps of what appears on an atomic or a molecular level. On the other hand,...
10.3K
Outcomes of Glycolysis01:13

Outcomes of Glycolysis

Nearly all the energy used by cells comes from the bonds that make up complex organic compounds. These organic compounds are broken down into simpler molecules, such as glucose. As a result, cells extract energy from glucose over many chemical reactions—a process called cellular respiration.
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
106.8K
Long-term Depression01:05

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
33.2K
Long-term Depression01:03

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
3.1K